FDA accepts Zelapar NDA

Amarin (AMRN) said the FDA accepted for review an NDA from Elan (ELN) for Zelapar selegiline oral dissolving tablet as an adjunct treatment to levodopa to treat Parkinson's disease. ELN has U.S. marke...